Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
Identifieur interne : 001475 ( PubMed/Corpus ); précédent : 001474; suivant : 001476Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
Auteurs : Melissa M. Coughlin ; Bellur S. PrabhakarSource :
- Reviews in medical virology [ 1099-1654 ] ; 2012.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (isolation & purification), Antibodies, Neutralizing (immunology), Antibodies, Neutralizing (isolation & purification), Antibodies, Viral (immunology), Antibodies, Viral (isolation & purification), Antiviral Agents (isolation & purification), Antiviral Agents (pharmacology), Epitopes (immunology), Humans, Immunotherapy (methods), Membrane Glycoproteins (antagonists & inhibitors), Membrane Glycoproteins (immunology), Mice, Mice, Transgenic, Protein Binding, SARS Virus (immunology), Severe Acute Respiratory Syndrome (therapy), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (antagonists & inhibitors), Viral Envelope Proteins (immunology).
- MESH :
- chemical , antagonists & inhibitors : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , isolation & purification : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- immunology : SARS Virus.
- methods : Immunotherapy.
- therapy : Severe Acute Respiratory Syndrome.
- Animals, Humans, Mice, Mice, Transgenic, Protein Binding, Spike Glycoprotein, Coronavirus.
Abstract
The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). hmAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS-CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain, and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs that can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS-CoV infection, and indicate that a similar approach may be applied to treat other viral infections.
DOI: 10.1002/rmv.706
PubMed: 21905149
Links to Exploration step
pubmed:21905149Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.</title><author><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M" last="Coughlin">Melissa M. Coughlin</name><affiliation><nlm:affiliation>Centers for Disease Control and Prevention, Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Atlanta, GA, USA. mcoughlin@cdc.gov</nlm:affiliation></affiliation></author><author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:21905149</idno><idno type="pmid">21905149</idno><idno type="doi">10.1002/rmv.706</idno><idno type="wicri:Area/PubMed/Corpus">001475</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001475</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.</title><author><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M" last="Coughlin">Melissa M. Coughlin</name><affiliation><nlm:affiliation>Centers for Disease Control and Prevention, Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Atlanta, GA, USA. mcoughlin@cdc.gov</nlm:affiliation></affiliation></author><author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name></author></analytic><series><title level="j">Reviews in medical virology</title><idno type="eISSN">1099-1654</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (isolation & purification)</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Neutralizing (isolation & purification)</term><term>Antibodies, Viral (immunology)</term><term>Antibodies, Viral (isolation & purification)</term><term>Antiviral Agents (isolation & purification)</term><term>Antiviral Agents (pharmacology)</term><term>Epitopes (immunology)</term><term>Humans</term><term>Immunotherapy (methods)</term><term>Membrane Glycoproteins (antagonists & inhibitors)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Transgenic</term><term>Protein Binding</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (antagonists & inhibitors)</term><term>Viral Envelope Proteins (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Epitopes</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Mice</term><term>Mice, Transgenic</term><term>Protein Binding</term><term>Spike Glycoprotein, Coronavirus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). hmAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS-CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain, and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs that can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS-CoV infection, and indicate that a similar approach may be applied to treat other viral infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21905149</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.</ArticleTitle><Pagination><MedlinePgn>2-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.706</ELocationID><Abstract><AbstractText>The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). hmAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS-CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain, and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs that can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS-CoV infection, and indicate that a similar approach may be applied to treat other viral infections.</AbstractText><CopyrightInformation>Copyright © 2011 John Wiley & Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coughlin</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Measles, Mumps, Rubella and Herpes Virus Laboratory Branch, Atlanta, GA, USA. mcoughlin@cdc.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Bellur S</ForeName><Initials>BS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AI082206</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI082206-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI082206-02</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U01AI077921-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21905149</ArticleId><ArticleId IdType="doi">10.1002/rmv.706</ArticleId><ArticleId IdType="pmc">PMC3256278</ArticleId><ArticleId IdType="mid">NIHMS334724</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005;2:73</Citation><ArticleIdList><ArticleId IdType="pubmed">16122388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2004 Apr;1(2):119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16212898</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2006 Jan;78(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16299724</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Struct Biol. 2005 Dec;15(6):664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16263266</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">16339146</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Feb;3(2):e27</Citation><ArticleIdList><ArticleId IdType="pubmed">16379499</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Res Rev. 2006 Jul;26(4):414-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16521129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Nov;80(21):10315-24</Citation><ArticleIdList><ArticleId IdType="pubmed">17041212</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Jul;3(7):e237</Citation><ArticleIdList><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2006;1:e24</Citation><ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2007 Feb;170(2):538-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17255322</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2006 Dec;12(12):1834-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17326933</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2007 Apr 25;361(1):93-102</Citation><ArticleIdList><ArticleId IdType="pubmed">17161858</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2007;152(6):1047-59</Citation><ArticleIdList><ArticleId IdType="pubmed">17516034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2007 Oct;25(10):1075-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17921981</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 2000 Feb;30(2):534-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10671209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Res. 2000 Mar;47(3):351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10709734</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2002 Sep;2(9):706-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12209139</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1351</Citation><ArticleIdList><ArticleId IdType="pubmed">12775803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1773-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12781536</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Immunol. 2003 Sep;58(3):277-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12950672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2003 Dec;28(3):239-44</Citation><ArticleIdList><ArticleId IdType="pubmed">14522061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Sci. 2003 Nov-Dec;10(6 Pt 2):664-75</Citation><ArticleIdList><ArticleId IdType="pubmed">14631105</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Nov;81(21):12029-39</Citation><ArticleIdList><ArticleId IdType="pubmed">17715238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2007 Dec;25(12):1421-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18066039</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Apr;82(7):3220-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18199635</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Sep;82(17):8887-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18562523</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2008 Nov;4(11):e1000197</Citation><ArticleIdList><ArticleId IdType="pubmed">18989460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2009 Sep 18;387(2):326-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19595990</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2009 Nov 10;394(1):39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19748648</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2009 Dec;9(6):1185-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19800030</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Mar 15;201(6):946-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20144042</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Apr;84(7):3134-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19906932</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2010 Oct;9(10):767-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20811384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3289-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15731223</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathology. 2003 Dec;35(6):526-31</Citation><ArticleIdList><ArticleId IdType="pubmed">14660106</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2004 Feb;202(2):157-63</Citation><ArticleIdList><ArticleId IdType="pubmed">14743497</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S6-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15018126</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2004 Jun;203(2):622-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15141376</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8709-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15161975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jul;78(13):6938-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2004 Jul;10(7):676-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15214887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2004 Sep 1;120(1):87-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15234813</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2004 Aug;126(2):509-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15302738</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Sep 10;322(1):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15313178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2004 Sep 15;173(6):4030-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15356152</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1992 Feb;66(2):956-65</Citation><ArticleIdList><ArticleId IdType="pubmed">1309922</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 Sep;69(9):5269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">7636969</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15496474</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jan;79(1):503-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15596843</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(3):1635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15650189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(6):3401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15731234</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Pathol. 2005 Mar;36(3):303-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15791576</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jun;79(11):7195-206</Citation><ArticleIdList><ArticleId IdType="pubmed">15890958</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Jul 22;333(1):186-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15939399</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2005 Sep;77(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16032747</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2005 Sep;141(3):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16045740</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2005 Aug;167(2):455-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16049331</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet J. 2005 Sep;170(2):193-211</Citation><ArticleIdList><ArticleId IdType="pubmed">16129340</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Sep;79(18):11638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16140741</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2005 Sep;23(9):1117-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16151405</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1822-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16166506</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001475 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001475 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21905149
|texte= Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21905149" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |